Immunotherapy for Solid Tumors
Author Contributions
Conflicts of Interest
References
- Yuan, G.; Flores, N.M.; Hausmann, S.; Lofgren, S.M.; Kharchenko, V.; Angulo-Ibanez, M.; Sengupta, D.; Lu, X.; Czaban, I.; Azhibek, D.; et al. Elevated NSD3 histone methylation activity drives squamous cell lung cancer. Nature 2021, 590, 504–508. [Google Scholar] [CrossRef] [PubMed]
- Xu, D.; Liu, S.; Wu, X.; Marti, T.M.; Dorn, P.; Schmid, R.A.; Peng, R.-W.; Shu, Y. Dissecting the immunological profiles in NSD3-amplified LUSC through integrative multi-scale analyses. Cancers 2022, 14, 4997. [Google Scholar] [CrossRef] [PubMed]
- Walter, P.; Ron, D. The unfolded protein response: From stress pathway to homeostatic regulation. Science 2011, 334, 1081–1086. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Guezour, N.; Soussi, G.; Brosseau, S.; Abbar, B.; Naltet, C.; Vauchier, C.; Poté, N.; Hachon, L.; Namour, C.; Khalil, A.; et al. Grade 3–4 immune-related adverse events induced by immune checkpoint inhibitors in non-small-cell lung cancer (NSCLC) patients are correlated with better outcome: A real-life observational study. Cancers 2022, 14, 3878. [Google Scholar] [CrossRef] [PubMed]
- Evdokimova, V.; Gassmann, H.; Radvanyi, L.; Burdach, S.E.G. Current state of immunotherapy and mechanisms of immune evasion in ewing sarcoma and osteosarcoma. Cancers 2022, 15, 272. [Google Scholar] [CrossRef] [PubMed]
- Nakamura, K.; Asanuma, K.; Okamoto, T.; Yoshida, K.; Matsuyama, Y.; Kita, K.; Hagi, T.; Nakamura, T.; Sudo, A. GPR64, Screened from ewing sarcoma cells, is a potential target for antibody-based therapy for various sarcomas. Cancers 2022, 14, 814. [Google Scholar] [CrossRef] [PubMed]
- Kuske, M.; Haist, M.; Jung, T.; Grabbe, S.; Bros, M. Immunomodulatory properties of immune checkpoint inhibitors—More than boosting t-cell responses? Cancers 2022, 14, 1710. [Google Scholar] [CrossRef] [PubMed]
- Weersma, R.K.; Zhernakova, A.; Fu, J. Interaction between drugs and the gut microbiome. Gut 2020, 69, 1510–1519. [Google Scholar] [CrossRef] [PubMed]
- Rizzo, A.; Cusmai, A.; Giovannelli, F.; Acquafredda, S.; Rinaldi, L.; Misino, A.; Montagna, E.S.; Ungaro, V.; Lorusso, M.; Palmiotti, G. Impact of proton pump inhibitors and histamine-2-receptor antagonists on non-small cell lung cancer immunotherapy: A systematic review and meta-analysis. Cancers 2022, 14, 1404. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
de Saint Basile, H.; Maaradji, Z.; Fabre, E. Immunotherapy for Solid Tumors. Cancers 2023, 15, 1646. https://doi.org/10.3390/cancers15061646
de Saint Basile H, Maaradji Z, Fabre E. Immunotherapy for Solid Tumors. Cancers. 2023; 15(6):1646. https://doi.org/10.3390/cancers15061646
Chicago/Turabian Stylede Saint Basile, Hortense, Zineb Maaradji, and Elizabeth Fabre. 2023. "Immunotherapy for Solid Tumors" Cancers 15, no. 6: 1646. https://doi.org/10.3390/cancers15061646